Navigation Links
ATS Medical Announces Fourth Quarter and Full Year 2009 Results
Date:3/1/2010

's conclusion and will remain available for seven days. The replay can be accessed by dialing 888-286-8010 for domestic participants and 617-801-6888 for international callers, using the passcode 61737878.

Disclosure of Non-GAAP Financial Measures

ATS reports its financial results in accordance with generally accepted accounting principles ("GAAP"). In addition, from time to time, we include other measures in our releases which are not prepared in accordance with GAAP. Investors should consider these non-GAAP financial measures in addition to, not as a substitute for or as superior to, financial reporting measures prepared in accordance with GAAP. Non-GAAP financial measures used by ATS may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies. In this release we have included disclosures of the adjusted percentage increase in revenue (adjusted revenue growth) for the fourth quarter of 2009 as well as earnings before interest, taxes, depreciation and amortization (EBITDA) , for the fourth quarter and full year periods of 2009 and 2008.  Both of these disclosures are non-GAAP financial measures.  We use both EBITDA and adjusted revenue growth rates in our internal analysis and review of our operational performance. We believe that these non-GAAP measures provide investors with useful information in comparing our operational performance over different periods. By using these non-GAAP measures we believe investors get a better picture of the performance of our
'/>"/>

SOURCE ATS Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related medicine technology :

1. First Perry Baromedical Sigma Elite Hyperbaric Chamber with EMR Installed at Stillwater Medical Center
2. Briggs Medical Service Company Receives ISO Registration and CE Mark Certification
3. APC Group, Inc. Reports Multi-Year Deal with Medical Device Manufacturer
4. ATS Medical and Wisconsin Heart Hospital Announce First Human Robotic Endoscopic Aortic Valve Replacement in the Midwest
5. Medical Innovation, New Therapies Helping To Extend American Lives
6. Medical Device Manufacturer Guidant Charged in Failure to Report Defibrillator Safety Problems to FDA
7. TriReme Medical, Inc. Receives FDA 510K Clearance for Glider(TM) PTA Balloon Catheter
8. Chinas leading electronic systems design event to highlight next-generation medical, automotive and green power technologies
9. Sanmina-SCI Tatabanya, Hungary Facility Achieves ISO 13485 Certification for Medical Devices
10. PointCare Donates Diagnostic Tests to Haitian Clinics to Ensure Resumption of Critical HIV/AIDS Patient Care and Bolster Emergency Medical Treatment for Earthquake Victims
11. Solta Medical to Participate in 2nd Annual Lazard Capital Markets Medical Technology Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... India Drug Forecast and Market Analysis to ... PharmaPoint: Atopic Dermatitis - India Drug ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a ... needs of severely obese patients, today announced initial ... a selective inhibitor of methionine aminopeptidase 2 (MetAP2), ... form of genetic obesity.  These results showed improvements ...
(Date:1/14/2014)... 2014 InformEx, North America,s leading ... will hold the 30 th edition of its annual ... Center from January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... fine chemical and specialty chemical companies will take part in ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... May 15, 2012  Cardium Therapeutics (NYSE Amex: ... UK-based Angel Biomedical Limited, a subsidiary of Angel ... contract manufacturer, covering the manufacture of formulated collagen ... for marketing by the U.S. Food and Drug ...
... Novelos Therapeutics, Inc. (OTCQX: NVLT) , ... treatment and diagnosis of cancer, today announced that ... a U.S. multi-center Phase 1b dose-escalation trial of ... cancer patients with advanced solid tumors.  The first ...
Cached Medicine Technology:Cardium Announces Agreement With UK-Based Angel Biomedical For Excellagen Supply And Planned European Market Expansion 2Cardium Announces Agreement With UK-Based Angel Biomedical For Excellagen Supply And Planned European Market Expansion 3Cardium Announces Agreement With UK-Based Angel Biomedical For Excellagen Supply And Planned European Market Expansion 4Cardium Announces Agreement With UK-Based Angel Biomedical For Excellagen Supply And Planned European Market Expansion 5Cardium Announces Agreement With UK-Based Angel Biomedical For Excellagen Supply And Planned European Market Expansion 6Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic 2Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic 3Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic 4
(Date:4/20/2014)... PHILADELPHIA Researchers may have identified key genes linked ... pain than others, according to a study released today ... Neurology,s 66th Annual Meeting in Philadelphia, April 26 to ... significant because it provides an objective way to understand ... levels," said study author Tobore Onojjighofia, MD, MPH, with ...
(Date:4/18/2014)... have made a discovery that turns 160 years of ... material long known to be essential for the fast ... is not as ubiquitous as thought, according to a ... Harvard Stem Cell Institute (HSCI) and the University,s Department ... Professor Jeff Lichtman, of Harvard,s Department of Molecular and ...
(Date:4/18/2014)... (April 18, 2014) ― A new study in the ... patterns in health-related Google searches reveals a recurring pattern ... , Investigators from San Diego State University, ... Monday Campaigns, analyzed "healthy" Google searches (searches that included ... diet") originating in the U.S. from 2005 to 2012. ...
(Date:4/17/2014)... specifically associated with the risk of a difficult-to-diagnose ... of all breast cancer cases. , The largest ... invasive lobular carcinoma, gives researchers important clues to ... breast cancer, which can be missed through screening. ... journal PloS Genetics , was co-led by ...
(Date:4/17/2014)... California, San Diego School of Medicine report that older ... recent major loss are more likely to be compassionate ... is published in this month,s issue of the ... behaviors are associated with better health and well-being as ... to improve the outcomes of individuals whose deficits in ...
Breaking Medicine News(10 mins):Health News:Low tolerance for pain? The reason may be in your genes 2Health News:Finding turns neuroanatomy on its head 2Health News:Finding turns neuroanatomy on its head 3Health News:New research shows people are thinking about their health early in the week 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:The ilk of human kindness 2
... 6, 2010 (Philadelphia, PA) -- Src (short for sarcoma) ... in many cancer tumors, including medulloblastoma, the most common ... most promising targets for cancer therapy. A recent ... be effective in interfering with the cell cycle and ...
... Jens Bangsbo from the Department of Exercise and Sports ... intervention studies involving both men, women and children, who ... results from the studies are so remarkable that the ... are publishing a special edition issue entitled "Football ...
... wind up in ER during major U.S. holidays, researchers find, ... are injured during the holidays, it,s not too many chocolate ... damage, a new study shows. , Rather, it is the ... fall prey to, the researchers from Nationwide Children,s Hospital in ...
... ... Superfruit Companies , ... (Vocus) -- Tahitian Noni International (TNI) announced a new quarter of a million ... other product in the industry will measure up to Tahitian Noni Bioactive Beverages., , , ...
... ... Excellence in Financial Journalism Award from the New York State Society of Certified Public Accountants ... New York, NY ... CFO magazine , won an Excellence in Financial Journalism Award from the New York ...
... ... PeopleStreme Human Capital has announced a collaboration with SkillSoft ... its clients.,We are thrilled to collaborate with SkillSoft to provide SkillSoft’s ... is a clear leader in the provision of our technology enabled ...
Cached Medicine News:Health News:New pyrimidine compounds may lead to improved treatments for childhood brain cancer 2Health News:Scientists: Soccer improves health, fitness and social abilities 2Health News:Scientists: Soccer improves health, fitness and social abilities 3Health News:Scientists: Soccer improves health, fitness and social abilities 4Health News:Most Holiday Injuries to Kids Spurred by Everyday Mishaps 2Health News:Quarter of a Million Dollar Superfruit Challenge Announced 2Health News:CFO magazine Wins Excellence in Financial Journalism Award 2Health News:PeopleStreme Collaborates with SkillSoft for Learning Management Content 2
Drug controls sera available in three levels for the control of accuracy and percision for up to 18 analytes...
Sera available in three levels for the control of accuracy and precision for up to 31 analytes...
Human based material available in two levels for the control of accuracy and precision for upto 23 analytes....
Human based assayed sera available in three levels for the control of accuracy and precision for up to 25 analytes...
Medicine Products: